IDEC Pharmaceuticals Corporation Company Profile
IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, developmentand commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. IDEC Pharmaceuticals first commercial product, Rituxan, and their most advanced product candidate, IDEC-Y2B8, are for use in the treatment of certain B-cell NHLs. IDEC Pharmaceuticals are also developing products for the treatment of certain solid tumor cancers and various autoimmune diseases (such as lupus and psoriasis).
Location
3030 Callan Road
San Diego
CA
92121
United States of America
Contact
Phone: 858 431 8500
Fax: 619 550 8750
News Articles
Return to top bigbiotech list Summary Website: Biogen Headquarters: Massachusetts, USA Ticker Symbol: BIIB (Nasdaq Stock Exchange) IDP (Frankfurt Stock Exchange) SEC Link: Biogen Subsidiaries: Bi...
– More than 50 Company- and Partner-Sponsored Presentations from the Biogen Idec MS Franchise and Pipeline to be Presented at the MS Community's Largest Medical Meeting – Biogen Idec (NASDAQ: BIIB...
Biogen Idec, Eisai Team Up At Research Triangle Park Facilities
WESTON (dpa-AFX) - Biogen Idec Inc.(BIIB) and Eisai Inc. Wednesday announced that they have entered into an agreement pursuant to which Biogen Idec is expected to lease a portion of the Eisai Rese...
Biogen Idec sells benlysta royalty rights to DRI Capital
Biogen Idec and DRI Capital has sold to a DRI Capital managed fund its royalty and other rights relating to BENLYSTA (belimumab) to which Biogen Idec is entitled pursuant to a license agreement with H...
Biogen Idec and Eisai team up for oral solid dose products
Biogen Idec and Eisai will bolster the manufacturing capabilities of both companies Research Triangle Park-based facilities. Under the terms of the agreement, Biogen Idec will lease a portion of the E...
Deciding to bet on dexpramipexole, an experimental drug for ALS, was one of the first bets made by Biogen Idec chief executive George Scangos when he arrived at the company. Now the medicine has faile...
Biogen Idec awards $100,000 to launch STEM education collaboration with Teach for America
The Biogen Idec Foundation and Teach For America announced a new collaboration in support of Science, Technology, Engineering, and Math (STEM) education. A $100,000 grant from The Biogen Idec Foundati...
FDA to review Biogen Idec's hemophilia B therapy
Biogen Idec Inc. (NASDAQ:BIIB) said FDA accepted for review a BLA for rFIXFc to treat hemophilia B. Biogen Idec said the application was submitted during 4Q12; a standard review would place the PDUFA...
Drugs and Medications
Indium in 111 chloride [Mallinckrodt Inc.]
Indiclorhigh purity indium chloride in-111 sterile solution [Amersham Health]
INDICLORHigh Purity Indium Chloride In-111 Sterile Solution
AVONEX (Interferon beta-1a)IM Injection
AVONEX (Interferon beta-1a)IM Injection
PubMed Articles
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the CNS associated with the JC virus. W...
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of th...
Natalizumab and HSV meningitis.
Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease....
Separation of nonfucosylated antibodies with immobilized FcγRIII receptors.
Post-translational modifications can dramatically impact protein activity, but identifying such structure:function relationships, as well as capitalizing on functionally enhanced variants, is a signif...
Design of next-generation protein therapeutics.
Since the first protein therapeutics were approved two decades ago, the field has seen a transition from the development of naturally occurring proteins to design of molecules engineered for optimal t...
Clinical Trials
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled I...
Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never b...
To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is...
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of...
This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: - to evaluate the safety and any harmf...
Companies
IDEC Pharmaceuticals Corporation
IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, developmentand commercialization of targeted therapies for the treatment of cancer and autoimmune and...
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...
Biogen Idec and Elan Corporation, plc
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in...
Biogen Idec and Portola Pharmaceuticals
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in...
More Information about "IDEC Pharmaceuticals Corporation" on BioPortfolio
We have published hundreds of IDEC Pharmaceuticals Corporation news stories on BioPortfolio along with dozens of IDEC Pharmaceuticals Corporation Clinical Trials and PubMed Articles about IDEC Pharmaceuticals Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of IDEC Pharmaceuticals Corporation Companies in our database. You can also find out about relevant IDEC Pharmaceuticals Corporation Drugs and Medications on this site too.
